Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?

doi:10.3748/wjg.v18.i44.6376

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2709)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

327

HTML

2266

Tables (1-1)

116

Sum=2709

Nov 28, 2012 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Field Of Vision

World J Gastroenterol. Nov 28, 2012; 18(44): 6376-6378
Published online Nov 28, 2012. doi: 10.3748/wjg.v18.i44.6376

Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?

Hendrik-Tobias Arkenau, Matilde Saggese, Charlotte Lemech

Hendrik-Tobias Arkenau, Matilde Saggese, Charlotte Lemech, Drug Development Unit, Sarah Cannon Research UK, University College London, London W1G 6AD, United Kingdom

Author contributions: Arkenau HT wrote the manuscript supported by Saggese M and Lemech C.

Correspondence to: Dr. Hendrik-Tobias Arkenau, PhD, Drug Development Unit, Sarah Cannon Research UK, University College London, 93 Harley Street, London W1G 6AD, United Kingdom. tobias.arkenau@sarahcannonresearch.co.uk

Telephone: +44-203-2195251 Fax: +44-207-0348465

Received: July 19, 2012
Revised: September 25, 2012
Accepted: September 29, 2012
Published online: November 28, 2012

Core Tip